Gemcitabine Plus S-1 as First-line Chemotherapy in Chinese Patients With Advanced Pancreatic Cancer: A Prospective Study

被引：0
|
作者：
Wu, W. [1 ]
Zheng, Y. [1 ]
Jiang, W. [1 ]
Liu, L. [1 ]
Tong, Z. [1 ]
Zhang, H. [1 ]
Fang, W. [1 ]
Zhao, P. [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
PANCREAS | 2019年 / 48卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1548 / 1548
页数：1
相关论文
共 50 条
  • [11] First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study
    Akitaka Makiyama
    Kenji Kunieda
    Masaaki Noguchi
    Takeshi Kajiwara
    Takao Tamura
    Koji Takeda
    Junko Sugiyama
    Keiko Minashi
    Toshikazu Moriwaki
    Naotoshi Sugimoto
    Michitaka Nagase
    Yuji Negoro
    Takashi Tsuda
    Hideki Shimodaira
    Naohiro Okano
    Akihito Tsuji
    Daisuke Sakai
    Kazuhiro Yanagihara
    Shinya Ueda
    Shingo Tamura
    Satoshi Otsu
    Takuya Honda
    Yuzo Matsushita
    Tatsuya Okuno
    Tomomi Kashiwada
    Akira Nozaki
    Masahide Ebi
    Hiroyuki Okuda
    Mototsugu Shimokawa
    Shuichi Hironaka
    Ichinosuke Hyodo
    Eishi Baba
    Narikazu Boku
    Kei Muro
    Taito Esaki
    Gastric Cancer, 2018, 21 : 792 - 801
  • [12] First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study
    Makiyama, Akitaka
    Kunieda, Kenji
    Noguchi, Masaaki
    Kajiwara, Takeshi
    Tamura, Takao
    Takeda, Koji
    Sugiyama, Junko
    Minashi, Keiko
    Moriwaki, Toshikazu
    Sugimoto, Naotoshi
    Nagase, Michitaka
    Negoro, Yuji
    Tsuda, Takashi
    Shimodaira, Hideki
    Okano, Naohiro
    Tsuji, Akihito
    Sakai, Daisuke
    Yanagihara, Kazuhiro
    Ueda, Shinya
    Tamura, Shingo
    Otsu, Satoshi
    Honda, Takuya
    Matsushita, Yuzo
    Okuno, Tatsuya
    Kashiwada, Tomomi
    Nozaki, Akira
    Ebi, Masahide
    Okuda, Hiroyuki
    Shimokawa, Mototsugu
    Hironaka, Shuichi
    Hyodo, Ichinosuke
    Baba, Eishi
    Boku, Narikazu
    Muro, Kei
    Esaki, Taito
    GASTRIC CANCER, 2018, 21 (05) : 792 - 801
  • [13] A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer
    Cui, Hanzhi
    Guan, Jingzhi
    Deng, Guochao
    Yuan, Jiajia
    Lou, Changjie
    Zhang, Wen
    Zhou, Aiping
    Zhang, Yanqiao
    Zhou, Jun
    Dai, Guanghai
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [14] Clinical Study of S-1 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-Line Treatment for Elderly Patients with Advanced Gastric Cancer
    Bo Deng-feng
    Hu Xiu-fu
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2015, 3 (04): : 238 - 242
  • [15] A phase II multicentric trial of combined chemotherapy with gemcitabine plus S-1 in patients with advanced pancreatic cancer
    Ohkawa, S.
    Amano, A.
    Ueno, M.
    Miyakawa, K.
    Sugimori, K.
    Tanaka, K.
    Kida, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [16] Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Kato, Ryo
    Ueda, Masami
    Tsuda, Yujiro
    Nakashima, Shinsuke
    Ohta, Katsuya
    Matsuyama, Jin
    Ikenaga, Masakazu
    Tominaga, Shusei
    CANCER REPORTS, 2020, 3 (02)
  • [17] Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
    Su, Dan
    Jiao, Shun-Chang
    Wang, Li-Jie
    Shi, Wei-Wei
    Long, Yan-Yan
    Li, Juan
    Bai, Li
    TUMOR BIOLOGY, 2014, 35 (03) : 2313 - 2318
  • [18] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
    Guo Xi
    Xu Yaolin
    Ji Yuan
    Fan Yue
    Wang Dansong
    Jin Dayong
    Zhuang Rongyuan
    Wu Lili
    Lou Wenhui
    Zhou Yuhong
    Department of Medical Oncology
    Department of General Surgery
    Department of Pathology
    Department of Traditional Chinese Medicine
    Department of Radiotherapy
    胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
  • [19] Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Lu, Ming
    Shen, Lin
    Zhou, Jun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12657 - 12666
  • [20] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Steven J. Cohen
    Mark M. Zalupski
    Manuel R. Modiano
    Paul Conkling
    Yehuda Z. Patt
    Peg Davis
    Robert T. Dorr
    Michelle L. Boytim
    Evan M. Hersh
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 287 - 294
12345